Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
Open Access
- 8 January 2015
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 32 (7) , 2250-2258
Abstract
Purpose To study the self-association states of insulin degludec and insulin aspart alone and combined in pharmaceutical formulation and under conditions simulating the subcutaneous depot. Methods Formulations were made of 0.6 mM degludec at 3 and 5 Zn/6 insulin monomers, and 0.6 mM aspart (2 Zn/6 insulin monomers). Self-association was assessed using size-exclusion chromatography (SEC) monitored by UV and orthogonal reverse-phase chromatography. Results Simulating pharmaceutical formulation, degludec eluted as dihexamers, whereas aspart eluted as hexamers and monomers. Combining degludec at low zinc with aspart increased dihexamer content, indicating hybrid hexamer formation. At high zinc concentration, however, there was no evidence of this. Simulating the subcutaneous depot by removing preservative, degludec eluted as multihexamers and aspart as monomers. Aspart was incorporated into the multihexamer structures when combined with degludec at low zinc, but there was no such interaction with high-zinc degludec. SEC using progressively diluted concentrations of phenol and m-cresol showed that dissociation of aspart into monomers occurs before the formation of degludec multihexamers. Conclusion Insulins degludec and aspart can be combined without forming hybrid hexamers, but this combinability is dependent on zinc and preservative concentration, and requires that degludec is fully dihexameric before addition of aspart.Keywords
This publication has 20 references indexed in Scilit:
- Variability of glucose‐lowering effect as a limiting factor in optimizing basal insulin therapy: a reviewDiabetes, Obesity and Metabolism, 2013
- A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog DetemirDiabetes Care, 2005
- The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human InsulinPharmaceutical Research, 2004
- Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 DiabetesDiabetes, 2004
- New insulins in the treatment of diabetes mellitusBest Practice & Research Clinical Gastroenterology, 2002
- Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.Diabetes, 2000
- Insulin glargineThe Lancet, 2000
- Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.Diabetes Care, 2000
- Non-Insulin-Dependent Diabetes Mellitus — A Genetically Programmed Failure of the Beta Cell to Compensate for Insulin ResistanceNew England Journal of Medicine, 1996
- Role of zinc in insulin biosynthesisDiabetologia, 1980